Skip to main content
SpringerLink
Log in

Neuroendokrine Tumoren in der Therapiekontrolle

  • Chapter
PET/CT-Atlas

  • 3798 Accesses

Zusammenfassung

Bei neuroendokrinen Tumoren sind die funktionell-metabolischen Verfahren der Bildgebung Standard. Sowohl unmittelbar nach Stellung der Diagnose (Primärstaging) als auch im Verlauf der Erkrankung (Therapieansprechen, Rezidivdiagnostik) sind diese unverzichtbar. Bei hoch differenzierten neuroendokrinen Tumoren (G1/G2) stehen konventionell szintigraphische Verfahren (In-111- und Tc-99m-Octreotid) zur Verfügung. Höhere diagnostische Aussagekraft bietet die PET(/CT) mit Ga-68 markierten Somatostatinanaloga (DOTATOC, DOTATATE). Diese Verfahren stellen auch die Bildgebung der Wahl zur Beurteilung der Möglichkeit einer Radiorezeptortherapie mit Y-90 oder Lu-177 markierten Somatostatinanaloga oder zur Verlaufsbeurteilung dar. Schlecht differenzierte neuroendokrine Tumoren (G3) sind mit oben genannten Verfahren weniger gut zu beurteilen, hier steht die PET(/CT) mit 18F-FDG zur Verfügung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) 68 Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39 (suppl 1): S52–60. doi:10.1007/s00259-011-1989-4

    Article  PubMed  Google Scholar 

  2. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52 (suppl 2): 42S–55 S

    Article  CAS  PubMed  Google Scholar 

  3. Antoch G, Kanja J, Bauer S et al. (2004) Comparison of PET, CT and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45: 357–365

    CAS  PubMed  Google Scholar 

  4. Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40: 1770–1780. doi 10.1007/s00259-013-2482-z

    Article  CAS  PubMed  Google Scholar 

  5. Goerres GW, Strupp R, Barghouth G et al. (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumors: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32: 153–162

    Article  CAS  PubMed  Google Scholar 

  6. Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52 (suppl 2): 56S–63 S

    Article  CAS  PubMed  Google Scholar 

  7. Haug AR, Auernhammer C, Wangler B et al. (2010) Neuroendocrine Tumors Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated 68 Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin. J Nucl Med 51: 1349–1356

    Article  CAS  PubMed  Google Scholar 

  8. Haug AR, Cindea-Drimus R, Auernhammer CJ et al. (2012) The Role of 68 Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors. J Nucl Med 53: 1686–1692. doi: 10.2967/jnumed.111.101675

    Article  CAS  PubMed  Google Scholar 

  9. Kabasakal L, Demirci E, Ocak M et al. (2012) Comparison of 68 Ga- DOTATATE PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39: 1271–1277

    Article  PubMed  Google Scholar 

  10. Kowalski J, Henze M, Schuhmacher J et al. (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5: 42–48

    Article  PubMed  Google Scholar 

  11. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenterapancreatic tumors. J Clin Oncol 2005 23: 2754–2762

    Article  CAS  PubMed  Google Scholar 

  12. Mottaghy FM, Reske SN (2006) Functional imaging of neuroendocrine tumours with PET. Pituitary 9: 237–242

    Article  CAS  PubMed  Google Scholar 

  13. Poeppel TD, Binse I, Petersenn S et al. (2011) 68 Ga-DOTATOC versus 68 Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 52: 1864–1870

    Article  CAS  PubMed  Google Scholar 

  14. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36: 228–247

    Article  PubMed  Google Scholar 

  15. Salazar R, Wiedenmann B, Rindi G, Ruszniewski P (2012) ENETS 2011 consensus guidelines for the management of patients with degestive neuroendocrine tumours: an update. Neuroendocrinology 95(2): 71–73. doi:10.1159/000335600

    Article  CAS  PubMed  Google Scholar 

  16. Scheidhauer K, Miederer M, Gaertner FC (2009) PET-CT bei neuroendokrinen Tumoren und nuklearmedizinische Therapiemoglichkeiten. Radiologe 49: 217–223. doi 10.1007/s00117-008-1784-9

    Article  CAS  PubMed  Google Scholar 

  17. Sundin A, Garske U, Orlefors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res 21: 69–85

    Article  CAS  Google Scholar 

  18. Teunissen JJ, Kwekkeboom DJ, Krenning EP (2004) Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Try3]octreotate. J Clin Oncol 22: 2724–2729

    Article  CAS  PubMed  Google Scholar 

  19. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V (2012) Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42: 80–87. doi 10.1007/s12020-012-9631-1

    Article  CAS  PubMed  Google Scholar 

  20. Valkema R, Pauwels S, Kvols LK et al. (2006) Survival and response after peptide receptor radionuclide therapy with [90YDOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147–156

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin

    Prof. Dr. med. Stefan Dresel

Authors
  1. Prof. Dr. med. Stefan Dresel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Wolfgang Mohnike

  2. Königstein, Deutschland

    Gustav Hör

  3. Klinikum für Nuklearmedizin, Klinikum Fulda, Fulda, Deutschland

    Andreas Hertel

  4. UCLA Molecular & Medical Pharmacology, Los Angeles, CA, USA

    Heinrich Schelbert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dresel, S. (2016). Neuroendokrine Tumoren in der Therapiekontrolle. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48842-3_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48841-6

  • Online ISBN: 978-3-662-48842-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation